Phosphodiesterase inhibition with tadalafil provides longer and sustained protection of stem cells

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 299, Issue 5, 2010, Pages

  Haider, Husnain Kh ^a   Lee, Yun Jung ^a   Jiang, Shujia ^a   Ahmed, Rafeeq P H ^a   Ryon, Mok ^a   Ashraf, Muhammad ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Cytoprotection; Phosphodiesterase; Preconditioning; Stem cells; Tadalafil

Indexed keywords

CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; K 252A; KT 5823; PHOSPHODIESTERASE; SHORT HAIRPIN RNA; TADALAFIL;

ACUTE HEART INFARCTION; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; ENZYME INHIBITION; FEMALE; HEART FUNCTION; HEART VENTRICLE CONTRACTILITY; MALE; MESENCHYMAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TRANSTHORACIC ECHOCARDIOGRAPHY;

ANIMALS; CARBOLINES; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DOSE-RESPONSE RELATIONSHIP, DRUG; GRAFT SURVIVAL; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MODELS, ANIMAL; MYOCARDIAL INFARCTION; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, INBRED F344; TIME FACTORS;

EID: 78249259700     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00437.2010     Document Type: Article

References (28)

1. AHA. Heart Disease and Stroke Statistics, 2009 Update. http://www.americanheart.org/downloadable/heart/ 123783441267009Heart%20and%20Stroke%20Updatepdf, 2009.
2. Ahmad N, Wang Y, Ali AK, Ashraf M. Long acting phosphodiesterase inhibitor, tadalafil induces sustained cardioprotection against lethal ischemic injury. Am J Physiol Heart Circ Physiol 297: H387-H391, 2009.
3. Al-Ameri H, Kloner RA. Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors. Int J Impot Res 21: 149-157, 2009.
4. Das A, Smolenski A, Lohmann SM, Kukreja RC. Cyclic GMP-dependent protein kinase Ialpha attenuates necrosis and apoptosis following ischemia/ reoxygenation in adult cardiomyocyte. J Biol Chem 281: 38644-38652, 2006. (Pubitemid 46041989)
5. Feil R, Lohmann SM, de Jonge H, Walter U, Hofmann F. Cyclic GMP-dependent protein kinases and the cardiovascular system: insights from genetically modified mice. Circ Res 93: 907-916, 2003. (Pubitemid 37433228)
6. Foresta C, Lana A, Cabrelle A, Ferigo M, Caretta N, Garolla A, Palu G, Ferlin A. PDE-5 inhibitor, Vardenafil, increases circulating progenitor cells in humans. Int J Impot Res 17: 377-380, 2005. (Pubitemid 41025774)
7. Haider H, Ashraf M. Strategies to promote donor cell survival: combining preconditioning approach with stem cell transplantation. J Mol Cell Cardiol 45: 554-566, 2008.
8. Jiang S, Haider H, Idris NM, Salim A, Ashraf M. Supportive interaction between cell survival signaling and angiocompetent factors enhances donor cell survival and promotes angiomyogenesis for cardiac repair. Circ Res 99: 776-784, 2006. (Pubitemid 44498311)
9. Kass DA, Champion HC, Beavo JA. Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ Res 101: 1084-1095, 2007.
10. Kodani E, Xuan YT, Takano H, Shinmura K, Tang XL, Bolli R. Role of cyclic guanosine monophosphate in late preconditioning in conscious rabbits. Circulation 105: 3046-3052, 2002. (Pubitemid 34693840)
11. Krumenacker JS, Katsuki S, Kots A, Murad F. Differential expression of genes involved in cGMP-dependent nitric oxide signaling in murine embryonic stem (ES) cells and ES cell-derived cardiomyocytes. Nitric Oxide 14: 1-11, 2006. (Pubitemid 43063502)
12. Kukreja RC, Ockaili R, Salloum F, Yin C, Hawkins J, Das A, Xi L. Cardioprotection with phosphodiesterase-5 inhibition-a novel preconditioning strategy. J Mol Cell Cardiol 36: 165-173, 2004. (Pubitemid 38202344)
13. Kulkarni SK, Patil CS. Phosphodiesterase 5 enzyme and its inhibitors: update on pharmacological and therapeutical aspects. Methods Find Exp Clin Pharmacol 26: 789-799, 2004.
14. Lin CS, Lin G, Xin ZC, Lue TF. Expression, distribution and regulation of phosphodiesterase 5. Curr Pharm Des 12: 3439-3457, 2006.
15. Madhusoodanan KS, Murad F. NO-cGMP signaling and regenerative medicine involving stem cells. Neurochem Res 32: 681-694, 2007. (Pubitemid 46481298)
16. Montani D, Chaumais MC, Savale L, Natali D, Price LC, Jais X, Humbert M, Simonneau G, Sitbon O. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Adv Ther 26: 813-825, 2009.
17. Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, St. Aubin C, Webster L, Rebeyka IM, Ross DB, Light PE, Dyck JR, Michelakis ED. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 116: 238-248, 2007.
18. Niagara MI, Haider H, Jiang S, Ashraf M. Pharmacologically preconditioned skeletal myoblasts are resistant to oxidative stress and promote angiomyogenesis via release of paracrine factors in the infarcted heart. Circ Res 100: 545-555, 2007. (Pubitemid 46673264)
19. Oshita AK, Rothstein G, Lonngi G. cGMP stimulation of stem cell proliferation. Blood 49: 585-591, 1977. (Pubitemid 8080188)
20. Pekkinen M, Ahlstrom ME, Riehle U, Huttunen MM, Lamberg- Allardt CJ. Effects of phosphodiesterase 7 inhibition by RNA interference on the gene expression and differentiation of human mesenchymal stem cell-derived osteoblasts. Bone 43: 84-91, 2008.
21. Ravipati G, McClung JA, Aronow WS, Peterson SJ, Frishman WH. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease. Cardiol Rev 15: 76-86, 2007. (Pubitemid 46272443)
22. Rosen RC, Kostis JB. Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol 92: 9M-18M, 2003.
23. Rosen RC, Shaw JW. Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations. Int J Impot Res 18: 570-573, 2006.
24. Shujia J, Haider HK, Idris NM, Lu G, Ashraf M. Stable therapeutic effects of mesenchymal stem cell-based multiple gene delivery for cardiac repair. Cardiovasc Res 77: 525-533, 2008. (Pubitemid 351197668)
25. Supuran CT, Mastrolorenzo A, Barbaro G, Scozzafava A. Phosphodiesterase 5 inhibitors- drug design and differentiation based on selectivity, pharmacokinetic and efficacy profiles. Curr Pharm Des 12: 3459-3465, 2006. (Pubitemid 44400483)
26. Wang L, Gang Zhang Z, Lan Zhang R, Chopp M. Activation of the PI3-K/Akt pathway mediates cGMP enhanced-neurogenesis in the adult progenitor cells derived from the subventricular zone. J Cereb Blood Flow Metab 25: 1150-1158, 2005. (Pubitemid 41710741)
27. Zhang M, Koitabashi N, Nagayama T, Rambaran R, Feng N, Takimoto E, Koenke T, O'Rourke B, Champion HC, Crow MT, Kass DA. Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes. Cell Signal 20: 2231-2236, 2008.
28. Zhu B, Zhang L, Alexeyev M, Alvarez DF, Strada SJ, Stevens T. Type 5 phosphodiesterase expression is a critical determinant of the endothelial cell angiogenic phenotype. Am J Physiol Lung Cell Mol Physiol 296: L220-L228, 2009.